AG
DAWN

Artal Group’s Day One Biopharmaceuticals DAWN Stock Holding History

Artal Group’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500,000
Closed -$6.13M – 102
2023
Q3 		$6.13M Hold
500,000
– – 0.26% 52
2023
Q2 		$5.97M Buy
+500,000
New +$6.53M 0.19% 60

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Artal Group's DAWN Position: Q4 2023 in Review

Artal Group sold out of Day One Biopharmaceuticals (DAWN) in Q4 2023, closing a stake of 500,000 shares — an estimated $6.13M sold.

Artal Group first reported a position in DAWN in Q2 2023 and held it in 2 quarters. The position peaked at $6.13M in Q3 2023. 139 funds tracked by Wall St. Rank hold DAWN as of Q4 2023.

  • Artal Group reported no remaining Day One Biopharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Artal Group sold 500,000 Day One Biopharmaceuticals shares in Q4 2023, an estimated $6.13M.
  • Artal Group first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Artal Group's Day One Biopharmaceuticals position peaked at $6.13M in Q3 2023.
  • 139 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.